An experimental treatment, gantenerumab, failed to help people at high risk of memory loss from Alzheimer’s or those who were in the early phases of the disease, the manufacturer said Monday.
Related Posts
Special counsel Jack Smith urges Supreme Court to reject Trump’s presidential immunity claim
- blkalertshealth
- April 9, 2024
- 0
In a court filing ahead of April 25 arguments, Smi